Clinical trials for glaucoma neuroprotection are not impossible

Related Experiment Video

Updated: May 25, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Harry A Quigley1

  • 1Glaucoma Services and Dana Center for Preventive Ophthalmology, Wilmer Ophthalmological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. hquigley@jhmi.edu

Current Opinion in Ophthalmology
|January 18, 2012
PubMed
Abstract

Insights

Developing new glaucoma treatments through neuroprotection faces challenges. This review outlines key design features to overcome barriers and successfully conduct neuroprotection trials for glaucoma.

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Pharmacology

Background:

  • Glaucoma is a leading cause of irreversible blindness.
  • Current treatments primarily focus on lowering intraocular pressure.
  • Neuroprotection offers a promising strategy to preserve retinal ganglion cells in glaucoma.

Purpose of the Study:

  • To identify and discuss critical issues impacting the development of novel neuroprotection therapies for glaucoma.
  • To review the challenges and barriers encountered in clinical trials for glaucoma neuroprotection.

Main Methods:

  • Literature review of existing neuroprotection strategies and clinical trial designs for glaucoma.
  • Analysis of barriers to successful trial implementation.
  • Synthesis of recommendations for optimizing trial design.

Main Results:

  • Significant barriers exist in designing and executing neuroprotection trials for glaucoma.
  • These barriers include patient selection, outcome measures, and trial duration.
  • Specific design features are crucial for trial success.

Conclusions:

  • Neuroprotection trials for glaucoma can be effectively conducted.
  • Implementing discussed design features is essential for advancing glaucoma neuroprotection therapies.
  • Overcoming trial barriers will facilitate the development of sight-saving treatments.

More Related Videos

Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres06:35

Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres

Published on: February 2, 2015

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...